Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

NeuroClues: the clinical must-have for Neurologists: clinical validation, industrialization, and go-to-market.

Project description

Medical device for accurate movement disorder diagnosis

NeuroClues is a groundbreaking portable, fast, and easy-to-use eye-tracking medical device that integrates clinically validated eye movement biomarkers for movement disorders (MDs) into neurologists’ clinical routines. With this in mind, the EIC-funded NeuroClues project aims to help neurologists make faster and more accurate diagnoses, reducing the diagnostic timeline from months to days and enabling earlier patient care. The project will validate NeuroClues’ integration into clinical practice with key opinion leader neurologists and assess its clinical value through ongoing studies in the EU and US. This validation is essential for gaining widespread acceptance among neurologists. Successful demonstration, combined with a strong go-to-market strategy, will position the developer, P3Lab, to be investor-ready by 2024 and profitable by 2027.

Objective

P3Lab developed NeuroClues, a first-of-a-kind portable, fast and easy to use eye tracking medical device that brings clinically validated eye movement biomarkers for movement disorders (MDs) into the clinical routine of neurologists. NeuroClues will enable neurologists to establish their MD diagnosis faster (from months to days) earlier and more reliably, and with diagnostic grade accuracy. This will enable neurologists to start patient care earlier. This project aims at validating and demonstrating (I) the usability of NeuroClues in the clinical routine with early adopter KOL neurologists and (II) assess its clinical value in ongoing and (III) in own sponsored clinical investigation studies (EU and US). This is needed to convince the broad majority of neurologist of NeuroClues’ clinical value. The successful demonstration and accompanied development of our go-to-market strategy will enable P3Lab to become investor ready by 2024 and profitable by 2027, with €70M ARR targeted by 2030.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

P3 LAB
Net EU contribution
€ 2 500 000,00
Address
RUE DU MORIMONT 33
1341 OTTIGNIES-LOUVAIN-LA-NEUVE
Belgium
SME
Yes
Region
Région wallonne Prov. Brabant Wallon Arr. Nivelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 5 557 786,50